Nicotine Gum Global Market Report 2024

The nicotine gum market size has grown strongly in recent years. It will grow from $1.66 billion in 2023 to $1.75 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth observed in the historic period for nicotine gum can be ascribed to several contributing factors. Smoking cessation programs have played a crucial role, providing structured support and resources to individuals aiming to quit smoking. Additionally, public health campaigns against smoking have raised awareness about the health risks associated with tobacco use, encouraging more individuals to seek effective methods for quitting.

Regulatory support for smoking cessation aids has also been instrumental, creating an environment that promotes and facilitates the availability of products such as nicotine gum. Physician recommendations have further bolstered the adoption of nicotine gum, as healthcare professionals advocate for its use as part of smoking cessation strategies. The consumer preference for self-help methods has been a significant driver as well, with individuals opting for accessible and over-the-counter solutions such as nicotine gum to address their smoking cessation goals. Overall, the synergy of these factors has contributed to the growth of nicotine gum in the historic period.

The nicotine gum market size is expected to see strong growth in the next few years. It will grow to $2.19 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The projected expansion during the forecast period can be ascribed to worldwide anti-smoking campaigns, heightened attention to mental health and addiction issues, an upsurge in regulations concerning e-cigarettes, and a growing awareness among consumers regarding health matters. Key trends anticipated in the forecast period encompass the launch of flavored nicotine gums, advancements in formulations, the integration of telemedicine and remote support services, and strategic collaborations with healthcare providers.

The anticipated increase in deaths attributable to smoking is poised to drive the expansion of the nicotine gum market in the foreseeable future. Smoking, encompassing the inhalation and exhalation of gases produced by burning plant materials such as marijuana, hashish, or tobacco in various forms, remains a significant health concern. Nicotine gum, positioned as a nicotine replacement therapy (NRT), delivers a controlled nicotine dose devoid of the harmful compounds found in tobacco smoke. This aids individuals in smoking cessation or reducing tobacco consumption. The gum can be taken every two hours independently to alleviate withdrawal symptoms or used as needed alongside a nicotine patch for managing intense cravings. Notably, recent statistics from the Centers for Disease Control and Prevention (CDC) reveal that cigarette smoking is the leading cause of preventable diseases and deaths in the United States, contributing to over 480,000 fatalities annually or one in five deaths. Similarly, global data from the World Health Organization underscores that tobacco claims more than 8 million lives annually, with 7 million directly linked to tobacco use and 1.2 million associated with second-hand smoke exposure. Consequently, the escalating death toll from smoking is a key driver for the growth of the nicotine gum market.

The ascent in tobacco prices is anticipated to fuel the expansion of the nicotine gum market. Tobacco, a plant belonging to the Nicotiana genus, has witnessed increased costs. The relatively lower expense of nicotine gum, coupled with its proven effectiveness in aiding smoking cessation, positions it as a cost-effective and accessible solution. Recent data from the Office for National Statistics indicates a notable 9.4% rise in the average price of a king-size 20-pack of cigarettes in the UK, climbing from £11.52 ($14.63) in 2021 to £12.62 ($16.22) in 2022. Consequently, the surge in tobacco prices serves as a catalyst for the growth of the nicotine gum market.

The prevailing trend in the nicotine gum market revolves around strategic partnerships, with major companies strategically aligning themselves to fortify their market positions. Notably, key players in the nicotine gum industry are actively engaging in collaborative endeavors to enhance their competitive standing. An illustrative example is the March 2022 partnership between Nicorette, a prominent US-based smoking cessation brand specializing in nicotine gums, and Nicoderm CQ, a brand under GSK Consumer Healthcare, a leading US-based biopharmaceutical company. This strategic alliance resulted in a comprehensive brand update, introducing new visual language and assets. The objective of this collaboration is to establish a more personalized, inclusive, and emotionally resonant customer interaction across all channels. The overarching goal is to effectively address the evolving needs of smokers and provide innovative nicotine replacement therapy (NRT) solutions to facilitate nicotine-free goals. Similarly, in February 2022, Enorama Pharma AB, a Sweden-based pharmaceutical company, entered into a partnership with Betapharm Arzneimittel GmbH, a German pharmaceutical company. Together, they launched a generic nicotine chewing gum in the German market, branded as Nicotine beta, and are concurrently developing an online smoking cessation program. This collaborative effort underscores the strategic importance of partnerships in expanding market reach.

Major players in the nicotine gum sector are driving growth through innovation, particularly the introduction of novel products such as lozenges. Lozenges, defined as small medicated tablets or candies that dissolve slowly in the mouth, serve various purposes, including soothing sore throats or alleviating coughs. A case in point is the May 2023 announcement by Perrigo Company PLC, an Ireland-based provider of over-the-counter self-care products. Perrigo unveiled FDA-approved Nicotine Coated Mint Lozenges, available in two strengths (2 mg and 4 mg) over the counter. These lozenges are designed to assist individuals in managing withdrawal symptoms during smoking cessation efforts. The emphasis on innovation underscores the commitment of market leaders to diversify their product offerings and cater to evolving consumer preferences.

In September 2021, Philip Morris International Inc., a U.S.-based tobacco company, successfully completed the acquisition of Fertin Pharma A/S for a deal valued at DKK 5.1 billion (approximately USD 820 million). This strategic move is part of Philip Morris International Inc.'s initiative to develop a pipeline of smoke-free products, with the overarching goal of gradually phasing out traditional cigarettes. The acquisition also signals the company's commitment to long-term expansion beyond the tobacco and nicotine sectors, venturing into emerging markets such as self-care and well-being. Fertin Pharma A/S, based in Denmark, is known for its expertise in creating and manufacturing innovative pharmaceutical and well-being products, including notable offerings such as nicotine gums. The acquisition positions Philip Morris International Inc. to diversify its product portfolio and play a significant role in the evolving landscape of health-conscious consumer goods.

Major companies operating in the nicotine gum market report are Walgreen Co., Johnson & Johnson Ltd., Novartis AG, GlaxoSmithKline PLC, British American Tobacco PLC, Philip Morris International Inc., ITC Limited, Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Swisher International Group Inc, Glenmark Pharmaceuticals Limited, Enorama Pharma AB., Cambrex Corporation, Alkalon A/S, betapharm Arzneimittel GmbH, Jiachem Dentbio Co. Ltd. North America was the largest region in the nicotine gum market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nicotine gum market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The primary variations of nicotine gum include 2 mg, 4 mg, and 6 mg nicotine gums. The 2 mg nicotine gum is classified as a nicotine replacement therapy (NRT) product, containing 2 milligrams (mg) of nicotine per piece. It serves as a smoking cessation aid, effectively mitigating cravings and withdrawal symptoms linked to the cessation of smoking or chewing tobacco. These nicotine gums are offered in both flavored and plain varieties, and they are distributed through various channels. Retail pharmacies, specialty stores, online platforms, and other distribution channels cater to a diverse range of consumers, including those seeking support at withdrawal clinics, medical practices, individual smokers, and more. The accessibility of nicotine gum through these channels contributes to its widespread use as a smoking cessation aid.

The nicotine gum market research report is one of a series of new reports that provides nicotine gum market statistics, including nicotine gum industry global market size, regional shares, competitors with a nicotine gum market share, detailed nicotine gum market segments, market trends and opportunities, and any further data you may need to thrive in the nicotine gum industry. This nicotine gum market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The countries covered in the nicotine gum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nicotine gum market consists of sales of regular strengthen gums, extra-strength gums, and nicotine polacrilex gum. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.